SG11201903057XA - Treatment of cholangiocarcinoma with tpcs-2a induced photochemical internalisation of gemcitabine - Google Patents
Treatment of cholangiocarcinoma with tpcs-2a induced photochemical internalisation of gemcitabineInfo
- Publication number
- SG11201903057XA SG11201903057XA SG11201903057XA SG11201903057XA SG11201903057XA SG 11201903057X A SG11201903057X A SG 11201903057XA SG 11201903057X A SG11201903057X A SG 11201903057XA SG 11201903057X A SG11201903057X A SG 11201903057XA SG 11201903057X A SG11201903057X A SG 11201903057XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- oslo
- cholangiocarcinoma
- gemcitabine
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 April 2018 (19.04.2018) WIP0 1 PCT omit n OH 10 0 0111 INIM Ell MIME 011 (10) International Publication Number WO 2018/069536 Al (51) International Patent Classification: A61K 31/409 (2006.01) A61K 41/00 (2006.01) A61K 31/7068 (2006.01) A61P 35/00 (2006.01) A61K 33/24 (2006.01) (21) International Application Number: Published: — with international search report (Art. 21(3)) PCT/EP2017/076257 (22) International Filing Date: 13 October 2017 (13.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1617526.7 14 October 2016 (14.10.2016) GB 1704719.2 24 March 2017 (24.03.2017) GB (71) Applicant: PCI BIOTECH AS [NO/NO]; Ullern- chausseen 64, 0379 Oslo (NO). (72) Inventors: HOGSET, Anders; Rognerudveien 55, N-0681 Oslo (NO). WALDAY, Per Edvard; Drammensveien 104D, N-0273 Oslo (NO). SELBO, Pal Kristian; Anne Manes vei 9, N-0373 Oslo (NO). EIVINDVIK, Kristin; Lilleruts vei 41, N-1364 Fornebu (NO). FINNESAND, Lena; Solligrenda 22, N-0491 Oslo (NO). = (74) Agent: JONES, Elizabeth Louise; Dehns, St Bride's House, 10 Salisbury Square, London Greater London EC4Y 8JD (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 1-1 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). co (54) Title: TREATMENT OF CHOLANGIOCARCINOMA WITH TPCS-2A INDUCED PHOTOCHEMICAL INTERNALISATION OF GEMCITABINE \" (57) : The present invention provides TPCS2 a , gemcitabine and optionally another cytotoxic agent, preferably cisplatin, for C use in a method of treating a cholangiocarcinoma in a human patient comprising a photochemical internalization method. Related kits for performing the invention are also provided.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1617526.7A GB201617526D0 (en) | 2016-10-14 | 2016-10-14 | Method |
GBGB1704719.2A GB201704719D0 (en) | 2017-03-24 | 2017-03-24 | Method |
PCT/EP2017/076257 WO2018069536A1 (en) | 2016-10-14 | 2017-10-13 | Treatment of cholangiocarcinoma with tpcs-2a induced photochemical internalisation of gemcitabine |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201903057XA true SG11201903057XA (en) | 2019-05-30 |
Family
ID=60186250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201903057XA SG11201903057XA (en) | 2016-10-14 | 2017-10-13 | Treatment of cholangiocarcinoma with tpcs-2a induced photochemical internalisation of gemcitabine |
Country Status (13)
Country | Link |
---|---|
US (1) | US20200338044A1 (en) |
EP (1) | EP3525783B1 (en) |
JP (1) | JP2019530718A (en) |
KR (1) | KR20190068573A (en) |
CN (1) | CN110022874A (en) |
AU (1) | AU2017342086A1 (en) |
CA (1) | CA3040344A1 (en) |
DK (1) | DK3525783T3 (en) |
ES (1) | ES2841941T3 (en) |
PL (1) | PL3525783T3 (en) |
RU (1) | RU2019109682A (en) |
SG (1) | SG11201903057XA (en) |
WO (1) | WO2018069536A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201913124D0 (en) * | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
GB201913121D0 (en) * | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO180167C (en) | 1994-09-08 | 1997-02-26 | Photocure As | Photochemical method for introducing molecules into the cytosol of cells |
GB9905911D0 (en) | 1999-03-15 | 1999-05-05 | Photocure As | Method |
WO2002044396A1 (en) | 2000-11-29 | 2002-06-06 | Pci Biotech As | Photochemical internalization for delivery of molecules into the cytosol |
GB0121023D0 (en) | 2001-08-30 | 2001-10-24 | Norwegian Radium Hospital Res | Compound |
GB0914286D0 (en) * | 2009-08-14 | 2009-09-30 | Pci Biotech As | Method |
GB0914287D0 (en) | 2009-08-14 | 2009-09-30 | Pci Biotech As | Compositions |
-
2017
- 2017-10-13 RU RU2019109682A patent/RU2019109682A/en not_active Application Discontinuation
- 2017-10-13 SG SG11201903057XA patent/SG11201903057XA/en unknown
- 2017-10-13 EP EP17791004.9A patent/EP3525783B1/en active Active
- 2017-10-13 WO PCT/EP2017/076257 patent/WO2018069536A1/en unknown
- 2017-10-13 US US16/341,186 patent/US20200338044A1/en not_active Abandoned
- 2017-10-13 KR KR1020197013250A patent/KR20190068573A/en not_active Application Discontinuation
- 2017-10-13 CN CN201780073846.XA patent/CN110022874A/en active Pending
- 2017-10-13 DK DK17791004.9T patent/DK3525783T3/en active
- 2017-10-13 PL PL17791004T patent/PL3525783T3/en unknown
- 2017-10-13 AU AU2017342086A patent/AU2017342086A1/en not_active Abandoned
- 2017-10-13 JP JP2019519974A patent/JP2019530718A/en active Pending
- 2017-10-13 ES ES17791004T patent/ES2841941T3/en active Active
- 2017-10-13 CA CA3040344A patent/CA3040344A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA3040344A1 (en) | 2018-04-19 |
DK3525783T3 (en) | 2021-01-18 |
ES2841941T3 (en) | 2021-07-12 |
RU2019109682A (en) | 2020-11-16 |
US20200338044A1 (en) | 2020-10-29 |
CN110022874A (en) | 2019-07-16 |
EP3525783A1 (en) | 2019-08-21 |
EP3525783B1 (en) | 2020-12-16 |
KR20190068573A (en) | 2019-06-18 |
JP2019530718A (en) | 2019-10-24 |
RU2019109682A3 (en) | 2021-02-15 |
AU2017342086A1 (en) | 2019-05-09 |
PL3525783T3 (en) | 2021-04-19 |
WO2018069536A1 (en) | 2018-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201906431UA (en) | Method for the treatment of thromboembolism | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201804312RA (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
SG11201906885TA (en) | Methods for the administration of certain vmat2 inhibitors | |
SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201805229YA (en) | Means and methods for treating hbv | |
SG11201907402SA (en) | Population-based immunogenic peptide identification platform | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
SG11201907196YA (en) | Composition and methods for preventing radiation injury and promoting tissue regeneration | |
SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11201809341PA (en) | Mobile robot | |
SG11201900021PA (en) | Methods and compositions for the treatment of cancer | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
SG11201901347UA (en) | Compositions and methods for cancer immunotherapy |